People · Operator
Named in public records as an officer, director or promoter · active 2008–2024 · Biotechnology, Pharmaceuticals, Other Health Care, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cidara Therapeutics, Inc. | — | Biotechnology | Series D+ | $349.1M | $2.8B | 2014 |
| Tyra Biosciences, Inc. | — | Biotechnology | Series D+ | $200.0M | $2.5B | 2024 |
| Vineti, Inc. | — | Biotechnology | Series C | $115.7M | $2.8B | 2018 |
| Lycera Corp | — | Pharmaceuticals | Series B | $85.7M | $1.0B | 2009 |
| Eiger Biopharmaceuticals Inc | — | Biotechnology | Series A | $70.9M | $216.9M | 2008 |
| Alvine Pharmaceuticals Inc | — | Other Health Care | Series B | $47.0M | $133.1M | 2009 |
| PrimeraDx, Inc. | — | Biotechnology | Series B | $20.9M | $784.3M | 2009 |
| Cns Therapeutics Inc | — | Pharmaceuticals | Series A | $13.1M | $94.5M | 2009 |
| Sequel Pharmaceuticals Inc | — | Pharmaceuticals | Seed | $5.4M | $38.0M | 2009 |
| Annum Health, Inc. | — | Healthtech | Seed | $3.9M | $10.4M | 2016 |
| Ocera Therapeutics Inc | — | Biotechnology | Seed | $1.5M | $66.6M | 2012 |
Nina Kjellson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nina Kjellson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Kristina Burow | 1 | 16 |
| Michael Powell | 1 | 14 |
| Patrick Heron | 1 | 11 |
| John Foster | 1 | 10 |
| Emily Melton | 1 | 10 |
| SCOTT ROCKLAGE | 1 | 9 |
| Risa Stack | 1 | 9 |
| Manish Agarwal | 1 | 9 |
| Robert More | 1 | 7 |
| PAUL SEKHRI | 1 | 7 |
| Rowan Chapman | 1 | 7 |
| Ilan Zipkin | 1 | 6 |
| Peter McNerney | 1 | 6 |
| Eli Casdin | 1 | 6 |
| Pratik Shah | 1 | 5 |
| Alan Fuhrman | 1 | 5 |
| Eckard Weber, M.D. | 1 | 5 |
| Howard Rosen | 1 | 5 |
| David Lowe | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.